Abstract
Objective: To analyse the efficacy, correlations and adverse‐event profile of placebo therapy from the initial placebo run‐in period to beyond 2 years of treatment. Patients and methods: The effects of placebo therapy on prostate size, maximum urinary flow rate (Q max ) and symptoms were analysed, and adverse drug experiences documented, for a period of 25 months in 303 patients randomized to the placebo arm of a controlled trial evaluating finasteride in the treatment of BPH (the Canadian PROSPECT study). Results: For all variables, the values during follow‐up were significantly different from baseline ( P ≤0.001). Transrectal ultrasonography confirmed a progressive increase in prostate volume over 25 months (+8.4%) but Q max improved for the first 5 months (to 1.4 mL/s over baseline) and remained 1.0 mL/s more than baseline at 25 months. The total symptom score improved by −2.9 points in the first 2 months on placebo and was ultimately 2.3 points below baseline at 25 months. The extent of the placebo response for symptoms ( r =0.08, P =0.180) and Q max ( r =0.04, P =0.550) was independent of age, but the response correlated with the initial severity of symptoms ( r =−0.394, P ≤0.001) and initial Q max ( r =−0.134, P =0.023). Patients with a prostate of ≤40 mL had a clinically more important placebo response than those with larger prostates. In all, 246 patients (81.2%) reported adverse events thought to be secondary to placebo therapy. The most common complaint was urogenital (40.3%), specifically impotence (6.3%) and decreased libido (6.3%); 13.2% of patients discontinued placebo therapy because of significant adverse reactions. Conclusions: Placebo therapy rapidly produces a significant improvement in Q max and symptoms of BPH but also causes clinically important adverse effects. The beneficial effect fades but remains after 2 years.